This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Jakafi's Performance Fuel Incyte's (INCY) Q1 Earnings?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports first-quarter 2021 results.
Novartis (NVS) Collaborates with Roche for API of RA Drug Actemra
by Zacks Equity Research
Novartis (NVS) enters into an agreement with Roche for the manufacturing of the active pharmaceutical ingredient (API) for Actemra/RoActemra.
Celcuity (CELC) Soars on Agreement With Pfizer & Study Data
by Zacks Equity Research
Celcuity (CELC) is developing gedatolisib in combination with Pfizer's Ibrance and an endocrine therapy in breast cancer patients. It inks deal to gain exclusive rights to gedatolisib from Pfizer.
Novartis (NVS) Teams Up With Artios for Radioligand Therapies
by Zacks Equity Research
Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.
AbbVie (ABBV) Seeks Skyrizi Approval for Psoriatic Arthritis
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Skyrizi - psoriatic arthritis.
bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nod
by Zacks Equity Research
bluebird (BLUE) and partner Bristol Myers clinch an FDA approval for their chimeric antigen receptor T cell immunotherapy Abecma to address relapsed or refractory multiple myeloma.
Roche's (RHHBY) SMA Treatment Evrysdi Secures EC Approval
by Zacks Equity Research
Roche (RHHBY) gains a regulatory nod for its SMA treatment Evrysdi in Europe for patients aged two months and above.
Novartis (NVS) Gets EC Nod For Kesimpta in Relapsing Forms of MS
by Zacks Equity Research
The European Commission approves Novartis' (NVS) Kesimpta for the treatment of adult patients with relapsing forms of multiple sclerosis.
Novartis (NVS) Posts Positive Data From Prostate Cancer Study
by Zacks Equity Research
Novartis (NVS) reports positive data from the phase III VISION study evaluating its radioligand therapy, 177Lu-PSMA-617, in patients with advanced prostate cancer.
Ionis (IONS) Crashes as Roche-Partnered Huntington's Drug Fails
by Zacks Equity Research
Ionis (IONS) stock sinks as partner Roche stops dosing in a late-stage study on tominersen in Huntington's disease.
J&J's (JNJ) Multiple Sclerosis Drug Ponesimod Gets FDA Nod
by Zacks Equity Research
J&J's (JNJ) ponesimod demonstrated superior clinical efficacy in reducing annual relapses compared to Sanofi's Aubagio in clinical studies.
Pharma Stock Roundup: EU Nod for J&J COVID-19 Vaccine, Updates From LLY, GSK, MRK
by Kinjel Shah
Europe clears J&J's (JNJ) COVID-19 vaccine. Eli Lilly (LLY), Merck (MRK) and Glaxo (GSK) give update on their COVID-19 antibody/antiviral candidates.
Novartis' (NVS) NSCLC Drug Fails to Meet Primary Endpoint
by Zacks Equity Research
Novartis (NVS) pipeline candidate, canakinumab, fails to meet the primary endpoint in lung cancer study.
Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL
by Zacks Equity Research
Gilead's (GILD) CAR T-cell therapy gets a boost with the FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Novartis (NVS) & CureVac Collaborate for COVID-19 Vaccine
by Zacks Equity Research
Novartis (NVS) will manufacture the mRNA and bulk drug product for CureVac's COVID-19 vaccine candidate.
Pfizer's (PFE) Lorbrena Gets FDA Nod for First-Line Lung Cancer
by Zacks Equity Research
Pfizer's (PFE) label expansion application for Lorbrena as first-line treatment for metastatic lung cancer gets approval in the United States.
Top Analyst Reports for Tesla, Intel & Verizon
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Tesla (TSLA), Intel (INTC), and Verizon (VZ).
Acceleron (XLRN) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.
Pharma Stock Roundup: Coronavirus Vaccine Updates From PFE, AZN & JNJ
by Kinjel Shah
WHO authorizes emergency use of AstraZeneca's (AZN) COVID-19 vaccine. J&J (JNJ) seeks conditional approval for its COVID-19 vaccine in EU.
What's in the Cards for Intellia (NTLA) This Earnings Season?
by Zacks Equity Research
Intellia Therapeutics (NTLA) is likely to discuss the progress of its pipeline candidate on its fourth-quarter earnings call.
The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis
Alnylam's (ALNY) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Alnylam (ALNY) reported a wider-than-expected loss but revenues beat estimates in the fourth quarter of 2020.
Pharma Stock Roundup: AZN's Q4 Earnings, FDA Approval for LLY & SNY's Drugs
by Kinjel Shah
AstraZeneca (AZN) announces Q4 results. FDA approves Lilly's COVID-19 antibody cocktail & Sanofi's (SNY) Libtayo for a new indication.
Novartis (NVS) Gets Breakthrough Therapy Tag for Leukemia Drug
by Zacks Equity Research
Novartis' (NVS) asciminib gets Breakthrough Therapy tag by the FDA for the treatment of adult patients with Ph+ CML in chronic phase, previously treated with two or more tyrosine kinase inhibitors.
Bristol Myers (BMY) Gets FDA Approval for CAR T-Cell Therapy
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval of CAR T cell therapy, Breyanzi, for the treatment of lymphoma.